ENA101
/ Enara Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 03, 2025
Discovery and validation of DARKFOXTM, a novel alternative open reading frame of FOXM1 that is an attractive cancer antigen for peptide-HLA targeting immunotherapy
(SITC 2025)
- "Background Targeted immunotherapies are a highly promising treatment strategy for solid tumors, exemplified by the recent FDA approvals of tebentafusp and afamitresgene autoleucel, which target Class I peptide-HLA (pHLA) antigens...It is characterised by minimal presence in normal tissues, homogeneous intratumoral expression, and robust presentation by HLA on the surface of tumor cells. ENA101, an EnTiCE® bispecific T-cell engager targeting DARKFOX-A3, is currently in IND-enabling studies."
IO biomarker • Esophageal Adenocarcinoma • Esophageal Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXM1
August 19, 2025
Discovery and validation of DARKFOXTM, a novel alternative open reading frame of FOXM1 that is an attractive cancer antigen for peptide-HLA targeting immunotherapy
(SITC 2025)
- "Background Targeted immunotherapies are a highly promising treatment strategy for solid tumors, exemplified by the recent FDA approvals of tebentafusp and afamitresgene autoleucel, which target Class I peptide-HLA (pHLA) antigens...It is characterised by minimal presence in normal tissues, homogeneous intratumoral expression, and robust presentation by HLA on the surface of tumor cells. ENA101, an EnTiCE® bispecific T-cell engager targeting DARKFOX-A3, is currently in IND-enabling studies."
IO biomarker • Esophageal Adenocarcinoma • Esophageal Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXM1
November 04, 2025
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies
(GlobeNewswire)
- "Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025. DARKFOX demonstrates best-in-class target properties: high tumor specificity, homogeneous expression in tumors and high prevalence in significant patient populations including lung, breast and GI cancers....ENA101 is advancing into IND-enabling studies with clear development path to submission in 2026."
IND • Preclinical • Breast Cancer • Gastrointestinal Cancer • Non Small Cell Lung Cancer
1 to 3
Of
3
Go to page
1